Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace

Executive Summary

Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.

You may also be interested in...



Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos

Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.

R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track

FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.

R&D In Brief: Sucampo/Takeda, Amgen, Merck/Endocyte

Sucampo/Takeda stumble with new formulation of Amitiza; Amgen makes progress with melanoma vaccine T-Vec and PCSK9 inhibitor evolocumab; Merck/Endocyte see positive signs for vintafolide in lung cancer, positive opinion in ovarian.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel